FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027252093> ?p ?o ?g. }

• W2027252093 endingPage "58" @default.
• W2027252093 startingPage "58" @default.
• W2027252093 abstract "Critically ill patients often present increased insulin resistance and stress-induced hyperglycemia. Tight glycemic control aims to reduce blood glucose (BG) levels and variability while ensuring safety from hypoglycemia. This paper presents the results of the second Belgian clinical trial using the customizable STAR framework in a target-to-range control approach. The main objective is reducing measurement frequency while maintaining performance and safety of the glycemic control. The STAR-Liege 2 (SL2) protocol targeted the 100–140 mg/dL glycemic band and offered 2-hourly and 3-hourly interventions. Only insulin rates were adjusted, and nutrition inputs were left to the attending clinicians. This protocol restricted the forecasted risk of BG < 90 mg/dL to a 5% level using a stochastic model of insulin sensitivity to assess patient-specific responses to insulin and its future likely variability to optimize insulin interventions. The clinical trial was performed at the Centre Hospitalier Universitaire de Liege and included 9 patients. Results are compared to 24-hour pre-trial and 24-hour post-trial, but also to the results of the first pilot trial performed in Liege, STAR-Liege 1 (SL1). This trial was approved by the Ethics Committee of the Medical Faculty of the University of Liege (Liege, Belgium). During the SL2 trial, 91 measurements were taken over 194 hours. BG levels were tightly distributed: 54.9% of BG within 100–140 mg/dL, 40.7% were ≥ 140 mg/dL and 4.4% were < 100 mg/dL with no BG < 70 mg/dL. Comparing these results with 24-hour pre-trial and post-trial shows that SL2 reduced high and low BG levels and reduced glycemic variability. Nurses selected 3-hourly measurement only 5 of 16 times and overrode 12% of 91 recommended interventions (35% increased insulin rates and 65% decreased insulin rates). SL1 and SL2 present similar BG levels distribution (p > 0.05) with significantly reduced measurement frequency for SL2 (p < 0.05). The SL2 protocol succeeded in reducing clinical workload while maintaining safety and effectiveness of the glycemic control. SL2 was also shown to be safer and tighter than hospital control. Overall results validate the efficacy of significantly customizing the STAR framework." @default.
• W2027252093 created "2016-06-24" @default.
• W2027252093 creator A5007263806 @default.
• W2027252093 creator A5009017948 @default.
• W2027252093 creator A5018504920 @default.
• W2027252093 creator A5018874543 @default.
• W2027252093 creator A5040228101 @default.
• W2027252093 creator A5042144141 @default.
• W2027252093 creator A5053114029 @default.
• W2027252093 creator A5071026833 @default.
• W2027252093 creator A5086300091 @default.
• W2027252093 creator A5090427178 @default.
• W2027252093 date "2012-01-01" @default.
• W2027252093 modified "2023-10-18" @default.
• W2027252093 title "Second pilot trials of the STAR-Liege protocol for tight glycemic control in critically ill patients" @default.
• W2027252093 cites W1971436236 @default.
• W2027252093 cites W1978864042 @default.
• W2027252093 cites W1980717583 @default.
• W2027252093 cites W1981121993 @default.
• W2027252093 cites W1999231148 @default.
• W2027252093 cites W2004745302 @default.
• W2027252093 cites W2042723121 @default.
• W2027252093 cites W2055825441 @default.
• W2027252093 cites W2061412350 @default.
• W2027252093 cites W2077534740 @default.
• W2027252093 cites W2079569240 @default.
• W2027252093 cites W2089264242 @default.
• W2027252093 cites W2097202487 @default.
• W2027252093 cites W2107545755 @default.
• W2027252093 cites W2115387528 @default.
• W2027252093 cites W2125163474 @default.
• W2027252093 cites W2139706988 @default.
• W2027252093 cites W2148703802 @default.
• W2027252093 cites W2157775267 @default.
• W2027252093 cites W2158435758 @default.
• W2027252093 cites W2169968309 @default.
• W2027252093 doi "https://doi.org/10.1186/1475-925x-11-58" @default.
• W2027252093 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3511234" @default.
• W2027252093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22917085" @default.
• W2027252093 hasPublicationYear "2012" @default.
• W2027252093 type Work @default.
• W2027252093 sameAs 2027252093 @default.
• W2027252093 citedByCount "15" @default.
• W2027252093 countsByYear W20272520932012 @default.
• W2027252093 countsByYear W20272520932014 @default.
• W2027252093 countsByYear W20272520932015 @default.
• W2027252093 countsByYear W20272520932018 @default.
• W2027252093 countsByYear W20272520932019 @default.
• W2027252093 countsByYear W20272520932020 @default.
• W2027252093 countsByYear W20272520932021 @default.
• W2027252093 countsByYear W20272520932022 @default.
• W2027252093 crossrefType "journal-article" @default.
• W2027252093 hasAuthorship W2027252093A5007263806 @default.
• W2027252093 hasAuthorship W2027252093A5009017948 @default.
• W2027252093 hasAuthorship W2027252093A5018504920 @default.
• W2027252093 hasAuthorship W2027252093A5018874543 @default.
• W2027252093 hasAuthorship W2027252093A5040228101 @default.
• W2027252093 hasAuthorship W2027252093A5042144141 @default.
• W2027252093 hasAuthorship W2027252093A5053114029 @default.
• W2027252093 hasAuthorship W2027252093A5071026833 @default.
• W2027252093 hasAuthorship W2027252093A5086300091 @default.
• W2027252093 hasAuthorship W2027252093A5090427178 @default.
• W2027252093 hasBestOaLocation W20272520931 @default.
• W2027252093 hasConcept C118552586 @default.
• W2027252093 hasConcept C126322002 @default.
• W2027252093 hasConcept C142724271 @default.
• W2027252093 hasConcept C154945302 @default.
• W2027252093 hasConcept C168563851 @default.
• W2027252093 hasConcept C177713679 @default.
• W2027252093 hasConcept C194828623 @default.
• W2027252093 hasConcept C204787440 @default.
• W2027252093 hasConcept C27415008 @default.
• W2027252093 hasConcept C2779306644 @default.
• W2027252093 hasConcept C2780385302 @default.
• W2027252093 hasConcept C2780473172 @default.
• W2027252093 hasConcept C2780668416 @default.
• W2027252093 hasConcept C2991859549 @default.
• W2027252093 hasConcept C3019316490 @default.
• W2027252093 hasConcept C41008148 @default.
• W2027252093 hasConcept C535046627 @default.
• W2027252093 hasConcept C71924100 @default.
• W2027252093 hasConceptScore W2027252093C118552586 @default.
• W2027252093 hasConceptScore W2027252093C126322002 @default.
• W2027252093 hasConceptScore W2027252093C142724271 @default.
• W2027252093 hasConceptScore W2027252093C154945302 @default.
• W2027252093 hasConceptScore W2027252093C168563851 @default.
• W2027252093 hasConceptScore W2027252093C177713679 @default.
• W2027252093 hasConceptScore W2027252093C194828623 @default.
• W2027252093 hasConceptScore W2027252093C204787440 @default.
• W2027252093 hasConceptScore W2027252093C27415008 @default.
• W2027252093 hasConceptScore W2027252093C2779306644 @default.
• W2027252093 hasConceptScore W2027252093C2780385302 @default.
• W2027252093 hasConceptScore W2027252093C2780473172 @default.
• W2027252093 hasConceptScore W2027252093C2780668416 @default.
• W2027252093 hasConceptScore W2027252093C2991859549 @default.
• W2027252093 hasConceptScore W2027252093C3019316490 @default.
• W2027252093 hasConceptScore W2027252093C41008148 @default.
• W2027252093 hasConceptScore W2027252093C535046627 @default.

• next